News - Biotechnology

Filter

Current filters:

Biotechnology

Popular Filters

76 to 100 of 2220 results

Lonza invests in clinical antibody drug conjugate manufacturing

Lonza invests in clinical antibody drug conjugate manufacturing

11-06-2014

Swiss chemical supplier Lonza has announced plans for investment for technology and facility improvements…

BiotechnologyLonzaProduction

Achillion HCV program back on track, as FDA lifts sovaprevir study hold; initiates ACH-3422 dosing

Achillion HCV program back on track, as FDA lifts sovaprevir study hold; initiates ACH-3422 dosing

10-06-2014

US drugmaker Achillion has begun dosing ACH-3422, a uridine-analog nucleotide polymerase inhibitor, for…

ACH-3422AchillionAnti-viralsBiotechnologyRegulationResearchsovaprevir

arGEN-X partners on ARGX-110 for Waldenstrom’s macroglobulinemia

arGEN-X partners on ARGX-110 for Waldenstrom’s macroglobulinemia

10-06-2014

Dutch/Belgian preclinical stage biotech company arGEN-X, has entered into a partnership with The Leukemia…

arGEN-XARGX-110BiotechnologyHematologyOncologyResearch

Immunomedics gets orphan drug status for IMMU-132 in pancreatic cancer

Immunomedics gets orphan drug status for IMMU-132 in pancreatic cancer

10-06-2014

US biotech firm Immunomedics says that IMMU-132, its antibody-drug conjugate (ADC) for solid cancer therapy,…

BiotechnologyIMMU-132ImmunomedicsOncologyRegulationResearchUSA

Dendreon chief to step down for personal reasons

Dendreon chief to step down for personal reasons

10-06-2014

US biotech firm Dendreon revealed last evening that John Johnson plans to step down as president and…

BiotechnologyBoardroomDendreonManagementProvenge

Israel’s OphthaliX updates on clinical developments and strategic plans

09-06-2014

Israel-based OphthaliX, a majority-owned subsidiary of biotech firm Can-Fite BioPharma focussed on ophthalmic…

BiotechnologyCan-Fite BioPharmaLicensingOphthaliXOphthalmicsResearch

Orphan designation for Momenta Pharma’s necuparanib in pancreatic cancer

Orphan designation for Momenta Pharma’s necuparanib in pancreatic cancer

09-06-2014

USA-based Momenta Pharmaceuticals says that its novel oncology candidate, necuparanib (formerly M402),…

BiotechnologyMomenta PharmaceuticalsnecuparanibOncologyRegulationUSA

French Transparency agency backs Gilead’s new hepatitis C drug Sovaldi

French Transparency agency backs Gilead’s new hepatitis C drug Sovaldi

09-06-2014

There was good news for US antivirals major Gilead Sciences, when France’s health technology assessment…

Anti-viralsBiotechnologyFranceGilead SciencesPricingRegulationSovaldi

Biogen Idec’s Eloctate gains FDA approval

Biogen Idec’s Eloctate gains FDA approval

09-06-2014

The US Food and Drug Administration on Friday approved US biotech firm Biogen Idec’s Eloctate, antihemophilic…

Biogen IdecBiotechnologyEloctateHematologyRegulationSwedish Orphan BiovitrumUSA

CMO Rentschler expands single-use manufacturing capacities

06-06-2014

German contract manufacturing organization (CMO) Rentschler Biotechnologie has announced the addition…

BiotechnologyGermanyProductionRentschler Biotechnologie

KemPharm gets $60 million funding commitment from Deerfield

KemPharm gets $60 million funding commitment from Deerfield

06-06-2014

KemPharm, a clinical-stage US biopharmaceutical company, has entered into a $60 million financing agreement…

BiotechnologyFinancialKemPharmKP201NeurologicalResearch

Halozyme can resume PEGPH20 clinical program in pancreatic cancer

Halozyme can resume PEGPH20 clinical program in pancreatic cancer

05-06-2014

US biotech firm Halozyme Therapeutics saw its shares rise after revealing that the US Food and Drug Administration…

BiotechnologyHalozyme TherapeuticsOncologyPEGH20RegulationResearchUSA

Bristol-Myers Squibb extends research accord with Biocon unit Syngene

Bristol-Myers Squibb extends research accord with Biocon unit Syngene

05-06-2014

US pharma major Bristol-Myers Squibb and Syngene International, India’s largest contract research organization,…

BioconBiotechnologyBristol-Myers SquibbIndiaResearchSyngene

China’s API industry is leading world production says new report

China’s API industry is leading world production says new report

05-06-2014

China’s chemical drug preparation industry and active pharmaceutical ingredient (API) industry recorded…

BiotechnologyBusiness FinanceChinaProduction

AFFiRiS reports breakthrough in Alzheimer's disease with AD04

AFFiRiS reports breakthrough in Alzheimer's disease with AD04

05-06-2014

Austrian biotech firm AFFiRiS has released Phase II results with its proprietary AD04 vaccine, saying…

AD04AFFiRiSBiotechnologyGlaxoSmithKlineNeurologicalResearch

arGEN-X and Shire sign long term collaboration deal worth $20 million

arGEN-X and Shire sign long term collaboration deal worth $20 million

04-06-2014

Belgium-based preclinical stage biotech firm arGEN-X has entered into a long-term strategic alliance…

arGEN-XBiotechnologyBusiness FinanceEuropeHuman antibody discovery technologiesResearchShireShire Pharmaceuticals

Teva ready to pay up to $825 million for Labrys Biologics, and its novel migraine treatment

Teva ready to pay up to $825 million for Labrys Biologics, and its novel migraine treatment

03-06-2014

Israel generics giant Teva Pharmaceutical Industries has entered into a definitive agreement to acquire…

AmgenBiotechnologyLabrys BiologicsLBR-101Mergers & AcquisitionsNeurologicalTeva Pharmaceutical Industries

Kymab strengthens management team with two senior appointments

Kymab strengthens management team with two senior appointments

03-06-2014

UK-based monoclonal antibody biopharmaceutical company Kymab has announced the appointment of Steve Arkinstall…

BiotechnologyBoardroomKymabPharmaceuticalUK

UK life sciences meeting agrees adaptive licensing is a golden opportunity

UK life sciences meeting agrees adaptive licensing is a golden opportunity

03-06-2014

Adaptive licensing is a “golden opportunity” to demonstrate the strength of life sciences in the…

Association of the British Pharmaceutical IndustryBiotechnologyLicensingPharmaceutical sciencesUK

Biota Pharma plans restructuring following loss of BARDA contract

02-06-2014

USA-based Biota Pharmaceuticals has adopted a plan to restructure the company's operations following…

Anti-viralsBiota PharmaceuticalsBiotechnologyFinanciallaninamivirManagementUSA

GlaxoSmithKline surprises with mega-dollar deal for cancer program

GlaxoSmithKline surprises with mega-dollar deal for cancer program

02-06-2014

UK biotech firm Adaptimmune revealed this morning that it has entered into a collaboration and licensing…

AdaptimmuneBiotechnologyGlaxoSmithKlineLicensingOncologyResearch

ASCO 2014 kicks off with news on lenvatinib, Cyramza, olaparib and Recentin

ASCO 2014 kicks off with news on lenvatinib, Cyramza, olaparib and Recentin

01-06-2014

The 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) began on Friday in Chicago,…

AstraZenecaBiotechnologyCyramzaEisaiEli LillylenvatinibolaparibOncologyRecentinResearch

ASCO 2014: latest news on lapatinib and trastuzumab, and ibrutinib

ASCO 2014: latest news on lapatinib and trastuzumab, and ibrutinib

01-06-2014

There was more important news on investigational oncology products presented at the 2014 Annual Meeting…

BiotechnologyGlaxoSmithKlineibrutinibJanssen BiotechJohnson & JohnsonLapatinibOncologyPharmacyclicsResearchtrastuzumab

76 to 100 of 2220 results

Back to top